Mississauga, ON, July 15, 2026 /PRNewswire/ -- Septa Pharmaceuticals Inc., a rapidly growing leader in the Canadian healthcare sector, is proud to announce the successful acquisition of CeeNU® (Lomustine) from Bristol Myers Squibb, Canada as of June 29th, 2026. This strategic acquisition...
Bristol Myers Squibb is a New Jersey-based biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases.